The NAFLD patients showed an increased percentage of intermediate CD14+CD16+, pro-inflammatory monocytes compared to the controls (p < 0.0001) (Figure S1). The gene discussed is CD14; the disease is metabolic dysfunction-associated steatotic liver disease.